9
Nov
2023
Obesity Drug Rivalry Intensifies, Takeda’s Big FDA Week, & Vor Takes on AML
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
9
Nov
2023
Vor Bio Shows CRISPR’d Stem Cell Transplants Take Hold in AML Patients, Enable ADCs
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
7
Nov
2023
Kynexis Gets €57M to Pursue New Treatment Pathway for Schizophrenia
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
3
Nov
2023
ProfoundBio, Challenging ImmunoGen, Delivers Responses in First Clinical Trial
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
2
Nov
2023
Lilly Doubles Down on Base Editing, BioMarin CEO Exits, and Layoffs Mount
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
1
Nov
2023
Investing in the Future of Medicine: Reid Huber on The Long Run
Today’s guest on the The Long Run is Reid Huber. He’s a partner at Third Rock Ventures in Boston. Third Rock is known in biotech as one of the venture firms that creates new companies that seek to turn groundbreaking science into new medicines. Since its founding in 2007, Third Rock has put together a portfolio of 62 companies that... Read More
1
Nov
2023
Gate Bioscience, Backed by Versant, A16Z, Arch, Gets $60M to Block Protein Secretion
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
31
Oct
2023
Nimbus HPK1 Inhibitor Activates Immune System Against Tumors in Early Clinical Trial
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
26
Oct
2023
Merck’s ADC Wager, Roche Enters TL1A Rivalry, & OrbiMed Signals Time to Buy
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
24
Oct
2023
Aiolos Bio, With $245M from Atlas, Bain, Aims at TSLP for Asthma
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
19
Oct
2023
Thermo’s $3.1B Proteomics Bet, UCB’s Rare Two-Fer, & More Cutbacks
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
16
Oct
2023
Catching Cancer Early, Investing in Data and AI: Jeff Huber on The Long Run
Today’s guest on The Long Run is Jeff Huber. He’s the co-founder and general partner at Triatomic Capital. It’s a relatively new venture fund that seeks to back “century-defining” businesses in Engineered Biology, New Materials, Next Gen Compute, New Energy, & Automated Economy. Jeff and his fellow partners are looking at startups that collect and analyze data to address big... Read More
12
Oct
2023
Another GLP-1 Victory, Bayer Invests in Berkeley, & EU Tells Illumina to Divest
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
5
Oct
2023
An mRNA Nobel, Lilly Acquires Point, and Investment in Singapore
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
3
Oct
2023
Targeted Radiation for Cancer: Lori Lyons-Williams on The Long Run
Today’s guest on The Long Run is Lori Lyons-Williams. She’s the CEO of Menlo Park, Calif. and Vancouver, BC-based Abdera Therapeutics. Abdera is a startup developing targeted antibody drugs loaded with potent microdoses of radiation to give them extra tumor-killing punch. This type of treatment modality has been around for decades. Targeted radiation hasn’t lived up to the full potential... Read More
19
Sep
2023
Turning the Tables: Rob Perez Interviews Me on The Long Run
This episode is unusual. Many listeners know of Rob Perez. He’s an operating partner at General Atlantic, the former CEO of Cubist Pharmaceuticals, and the founder of Life Science Cares. Rob and I have gotten to know each other better the past couple years through our shared passion for mobilizing the biotech community to fight poverty. The Timmerman Traverse for... Read More
6
Sep
2023
Freeing the Biotech Founders: Zach Weinberg and Alexis Borisy on The Long Run
Today there are two guests on The Long Run: Zach Weinberg and Alexis Borisy. They are co-founders of Curie.Bio. Curie is a venture capital fund with $520 million, mostly for seed investments and Series A rounds in biotech startups. It also is also building up in-house R&D expertise which it uses to help the entrepreneurs it backs. Curie pitches itself... Read More
5
Sep
2023
A Return to Kilimanjaro: Timmerman Traverse for Damon Runyon Cancer Research
Welcome to the next big biotech expedition — Timmerman Traverse for Damon Runyon Cancer Research Foundation. A team of executives, investors, and scientists are coming together on Kilimanjaro, the highest peak in Africa, in February 2024. We’re on a mission to raise $1 million for young scientists across the US. Damon Runyon gives promising young researchers the freedom to pursue... Read More
31
Aug
2023
Danaher Wins Over Abcam, Sage Cuts, & FTC Ceases Fire With Amgen
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
24
Aug
2023
Rapport’s $150M Advance, Regeneron’s New COVID Challenge, and a Traverse for the Ages
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.